Menstrual Blood May Hold a Surprising Repair Kit for Aching Joints

A breakthrough for worn-out cartilage may come from an unlikely place: the menstrual blood most clinics discard without a second look.

Osteoarthritis has no cure. Once the smooth, rubbery tissue cushioning joints starts to break down, doctors can manage pain and swelling, but nothing available today can reverse the damage or regrow what’s lost. By global disease-burden estimates, roughly 600 million people worldwide live with the condition, a disproportionate number of them postmenopausal women, and that reality has remained stubbornly unchanged.

In a new study published in Scientific Reports, researchers found that microscopic particles harvested from menstrual blood can prompt damaged cartilage cells to produce the very building blocks they’ve lost. These particles are called extracellular vesicles, nano-sized packages that cells release to communicate with their neighbors. When researchers applied vesicles collected from stem-like cells in menstrual blood to human cartilage cells and tissue samples in the lab, they triggered a measurable uptick in the production of two proteins that keep joints functional and resilient.

What stands out here is where the particles come from. Menstrual blood can be collected painlessly, repeatedly, and without surgery, a sharp contrast to the bone marrow biopsies and fat tissue extractions that dominate stem cell research. Because the therapy uses only tiny vesicles rather than whole cells, it sidesteps some safety concerns tied to transplanting living cells into the body, such as the risk of tumor formation or immune rejection.

How Menstrual Blood Vesicles Were Tested on Cartilage

Researchers at the Innovative Medicine Center in Vilnius, Lithuania, along with colleagues at Vilnius University and Kaunas University of Technology, collected menstrual blood from three healthy donors aged 27, 32, and 34 during the second day of their menstrual cycles. From those samples, they isolated a stem-like cell type that naturally releases these vesicles.

By separating the vesicles by size, the team confirmed their identity by checking for three well-known surface markers. They then tested them on cartilage cells and cartilage tissue from 10 female donors aged 65 to 85 who had undergone joint surgery for advanced osteoarthritis.

Testing unfolded in stages. First, the researchers checked whether the vesicles could enter cartilage cells. Using a fluorescent dye to tag them, they found that cartilage cells efficiently absorbed the vesicles within just three hours. At the dose used, about 100 vesicles per cell, the particles didn’t cause the cells to behave abnormally. Movement patterns, cell shape, and the rate at which cells multiplied all remained comparable to untreated cells over seven days. None of these measures showed concerning changes.

Menstrual Blood Vesicles Helped Cartilage Cells Rebuild

More revealing results came from longer experiments. When cartilage cells were formed into three-dimensional pellets, small clumps designed to mimic the way cartilage grows in the body, and cultured for 21 days with both the vesicles and a growth-stimulating protein, they showed significantly higher activity in the genes responsible for producing the structural proteins that give cartilage its strength. Microscopic staining confirmed those results: treated pellets contained more of the molecules that make cartilage resilient.

A second set of experiments used intact cartilage tissue samples, which more closely resemble living joint tissue. Researchers exposed them to one of three conditions: a normal environment, an inflammatory environment designed to mimic what happens inside an arthritic joint, or a growth-promoting environment. In each scenario, some samples received the menstrual blood vesicles while others did not.

Results pointed the same way. Two indicators of cartilage breakdown were lower in vesicle-treated samples than in untreated ones across the conditions tested, though the effect was clearer in some groups than in others. Under inflammatory stress, vesicle-treated tissue retained noticeably more structural protein and staining than untreated tissue, suggesting the particles helped protect it from breaking apart.

A secondary measurement technique that analyzes how tissue absorbs infrared light backed up those visual findings. Researchers detected higher levels of protein and carbohydrate signatures in vesicle-treated samples, patterns consistent with the very molecules that give cartilage its shock-absorbing properties.

Gene activity analysis told a similar story. Cartilage treated with the vesicles showed significantly higher activity in genes tied to rebuilding, while genes linked to cartilage-destroying enzymes remained unchanged. In short, the vesicles encouraged cartilage-building activity without raising the activity of genes that break tissue down.

A Possible Hormone Connection to Osteoarthritis in Women

One unexpected wrinkle emerged. After just three days of exposure to the menstrual blood vesicles, cartilage cells showed a significant increase in progesterone receptor levels at both the protein level and in gene activity. Estrogen receptor levels, by contrast, stayed the same. That matters, because osteoarthritis rates spike in women after menopause, when levels of both estrogen and progesterone drop sharply. Progesterone receptors are involved in cartilage maintenance and cell survival, so the ability of these vesicles to boost their presence could offer clues about the joint deterioration many women experience later in life. Whether that receptor change actually translates into protection against osteoarthritis remains untested.

Another check looked at whether the vesicles triggered unwanted inflammatory responses. Using a panel that measured 45 different signaling molecules in both cell cultures and tissue samples, the researchers found that the vesicles largely did not alter the inflammatory profile of cartilage cells or tissue. One exception was a single molecule that changed after seven days in tissue cultures. Otherwise, the vesicles appeared to work without triggering a broader inflammatory response.

What This Means for Osteoarthritis Treatment

This is a lab study, and the distance between promising results in a dish and a working treatment in a doctor’s office is enormous. No one injected these vesicles into a living joint or tracked whether they prevented arthritis progression in an actual patient. But what the results do establish is that these tiny, cell-free particles from a routinely discarded biological fluid can meaningfully influence cartilage biology, encouraging cells to rebuild while reducing signs of tissue destruction, even under conditions designed to mimic the hostile environment of an arthritic joint.

For a disease that currently has no way to undo its damage, that is a lead very much worth following. And if it pans out, a fluid typically discarded without a second thought could become one of the more practical starting points for a new kind of joint therapy, one that doesn’t require surgery to collect and doesn’t carry the risks of transplanting living cells.

Disclaimer: This article describes early laboratory research. The experiments were conducted on isolated cells and donated tissue samples in a lab, not in living people or animals. No treatment has been tested in or approved for patients, and much more research is needed before these findings could lead to a therapy. Nothing here should be taken as medical advice.

---